Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with type 2 diabetes (T2D) and moderate renal impairment (estimated glomerular filtration rate Conclusions: The findings of this study (NCT02413398, clinicaltrials.gov) support the positive benefit/risk profile of dapagliflozin for the treatment of patients with T2D and CKD 3A.
of CKD. 2 Optimal glycaemic control in patients with diabetes and CKD is crucial, to reduce the risk of further complications, as well as the progression rate of CKD. 3 However, glucose-lowering treatment options in this population are limited, and several drugs have label restrictions concerning CKD. [3] [4] [5] Furthermore, patients with CKD are at greater risk of developing severe hypoglycaemia, and medications that carry a high risk of hypoglycaemia [3] [4] [5] [6] may be less appropriate for this population. New treatment options for patients with diabetes and CKD are therefore needed to optimize outcomes.
Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2) that causes glycosuria and lowers blood glucose levels regardless of insulin sensitivity and β-cell secretory function. 7, 8 Dapagliflozin is associated with reductions in blood pressure and body weight, 9,10 and carries a low intrinsic risk of hypoglycaemia. 11 SGLT2 inhibitors have also demonstrated cardiovascular (CV) and renal benefits. [12] [13] [14] [15] [16] Because dapagliflozin's mode of action is dependent on blood glucose levels and glomerular filtration rate (GFR), 17 its glucose-lowering effects are attenuated in patients with moderate renal impairment 18 (estimated GFR Further understanding regarding the use of dapagliflozin in the management of patients with T2D and CKD is thus required. Here we assess the efficacy and safety of dapagliflozin 10 mg in patients with T2D and CKD stage 3A (eGFR, 45-59 mL/min/1.73 m 2 ).
| MATERIALS AND METHODS

| Study design
This was a randomized, double-blind, 2-arm, parallel group, placebo-controlled, multinational, Phase 3 study to evaluate the efficacy and safety of dapagliflozin in patients with T2D and CKD stage 3A (eGFR, 45-59 mL/ min/1.73 m 2 ; based on the modification of diet in renal disease [MDRD] formula). 19 The study was conducted at 88 centres in the USA, Canada, Bulgaria, the Czech Republic, Italy, Poland, Spain and Sweden.
Patients were randomized (1:1) to 24 weeks of treatment with dapagliflozin 10 mg or matching placebo. The study consisted of a 2-week screening period, a 4-week single-blind placebo lead-in period, a 24-week double-blind treatment period and a 3-week posttreatment follow-up period. It was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines as defined by the International Conference on Harmonization. The study was approved by the institutional review boards and independent ethics committees of all participating centres. All participants provided written informed consent prior to inclusion in the study. This study is registered at ClinicalTrials.gov (NCT02413398) and the study protocol is available online: http://astrazenecagrouptrials.pharmacm.com.
| Participants
The study included male and female patients (≥18 to <75 years) who have had T2D for >12 months, inadequate glycaemic control (HbA1c ≥7.0%
and ≤11.0% at screening) and a body mass index (BMI) of 18- 
| Endpoints
The primary efficacy outcome was mean change from baseline in HbA1c 
| Randomization and masking
Eligible patients were assigned a unique randomization code using an interactive voice response system (IVRS) or interactive web response system (IWRS). For each randomized patient the IVRS/IWRS provided the investigator with a unique Kit ID number matching the treatment arm to which the patient was assigned.
| Statistical analysis 2.6.1 | Sample size
Assuming a common standard deviation (SD) of 0.9% in the primary endpoint, 143 patients per treatment group for whom both baseline and at least 1 post-baseline HbA1c measurements were available would provide 80% power to detect a predicted treatment difference of 0.3% in the primary endpoint at a 2-sided significance level of 0.05, using a 2-sample t-test. Assuming that 5% of randomized patients failed to qualify for inclusion in the full analysis set because of missing baseline and/or all post-randomization values for this primary endpoint, a total of 302 randomized patients, 151 per treatment group, were needed for the study.
| Efficacy analyses
Efficacy analyses were performed on the full analysis set, comprising all randomized patients who received at least 1 dose of double-blind study medication and for whom a baseline value and at least 1 postbaseline efficacy value were available. The primary efficacy analysis, change from baseline in HbA1c at Week 24, was based on a mixed effects model with repeated measures (MMRM) using "direct likelihood" which assumed that missing data were missing at random. The primary analysis included measurements before rescue medication or discontinuation of the double-blind study medication. The model included the fixed categorical effects of treatment, week, randomization stratification factor (glucose-lowering treatment strata) and treatment-by-week interaction, as well as the continuous fixed covariate effects of baseline measurement and baseline measurement-byweek interaction. Point estimates and 95% confidence intervals for mean change within each treatment group, as well as the difference in mean change estimates between the dapagliflozin and placebo groups, were calculated. P values for the differences in estimates at Week 24 between the dapagliflozin and placebo groups were also calculated and reported at the nominal level. A sequential testing procedure was employed to accommodate multiple comparisons, whereby tests for secondary efficacy endpoints (changes from baseline in body weight, FPG and seated SBP) were performed only if the primary endpoint comparison, and all previous ordered secondary comparisons, were significant. Secondary and exploratory endpoints were analysed using an MMRM, similar to the model used in the primary analysis. Analysis of covariance (ANCOVA) was used in exploratory analyses for endpoints measured at baseline and at the end of treatment using the last observation carried forward (LOCF). ANCOVA models contained fixed categorical effects for randomization stratification factor and treatment, and a fixed covariate effect for baseline measurement.
| Sensitivity analyses
Sensitivity analyses were conducted to assess the robustness of the primary analysis (Appendix S1).
| Safety analyses
Safety analyses were performed on the safety analysis set, comprising all patients who received at least 1 dose of double-blind study medication during the double-blind treatment period. Safety analyses were performed using descriptive statistics. Comparisons between dapagliflozin 10 mg and matching placebo were not made for safety variables and inferential testing was not performed.
For mean changes from baseline in eGFR, data over 24 weeks
were analysed with missing data assumptions specific to MMRM.
Data over the full 27-week period were analysed similarly through Week 27.
3 | RESULTS
| Patients
The study was conducted between June 15, 2015 and November 7, 2017. A total of 321 patients were randomized: 160 to the dapagliflozin 10 mg group and 161 to the placebo group ( Figure S1 a SBP data are based on the full analysis set (n = 158 for dapagliflozin, n = 161 for placebo); all other data are based on all randomized patients.
| Primary endpoint
| Exploratory endpoints
The adjusted proportion of patients achieving HbA1c <7% (95% CI) at 
| Safety outcomes
Dapagliflozin was well-tolerated and AEs were balanced between treatment arms, with numerically fewer AEs (41.9% vs 47.8%) and serious AEs (5.6% vs 8.7%) reported with dapagliflozin than with placebo, respectively ( Table 2 ). The proportion of AEs leading to 3) with placebo. CI, confidence interval; FPG, fasting plasma glucose; SBP, systolic blood pressure; SD, standard deviation discontinuation of study medication was also balanced between the dapagliflozin and placebo groups (1.9% in both). One patient in the dapagliflozin group had an eGFR value of 30.3 mL/min/1.73 m 2 that was registered by the investigator as an AE; however, eGFR returned to baseline following discontinuation of study medication. Patients in the dapagliflozin and placebo groups had similar percentages of urinary tract infections (2.5% vs 3.7%) and genital infections (1.9% vs 1.2%) ( Table 2 ).
Few AEs of hypotension/dehydration/hypovolaemia (1.9% vs 0.0%) or renal impairment/failure (0.6% vs 1.2%) were reported. No
AEs of bone fractures, amputations or DKA were reported and no patients had elevated liver enzymes or experienced liver-related AEs.
There were no meaningful changes in seated heart rate at Week The proportion of patients with hypoglycaemia was balanced between the dapagliflozin and placebo groups (12.5% vs 13.7%, respectively), with the majority of these patients receiving insulin (8.8% vs 11.8%, respectively) ( Table 3) . No patients discontinued study medication because of hypoglycaemia and no episodes of major hypoglycaemia were reported.
Decreases from baseline in eGFR were larger with dapagliflozin Placebo-corrected reductions in HbA1c of −0.34% were reported at Week 24, which, while lower than those in patients with normal renal function, [20] [21] [22] were almost identical to a post hoc analysis of the Kohan et al. study in patients with T2D and CKD stage 3A 18 and with a pooled analysis of 11 randomized controlled trials by Petrykiv et al. 23 The extent of HbA1c lowering in the current study was also similar to that observed with other SGLT2 inhibitors in patients with CKD stage 3.
24,25
The benefits concerning body weight and SBP that were independent of renal function in this study are in line with previous reports of benefits with the use of dapagliflozin. acid. 23 It is noteworthy that the reductions in SBP seen in our study with use of dapagliflozin were not accompanied by changes in heart rate. Previous studies indicate that higher resting heart rate and lower heart rate variability are both risk factors for end-stage renal disease (ESRD) and CKD-related hospitalizations. 26 Glucose-lowering treatments that reduce body weight and SBP without affecting heart rate may be particularly valuable in this population.
SGLT2 treatment is associated with a transient drop in eGFR that
is reversible after treatment discontinuation. 11, 25, 27 Findings from the current trial were consistent with findings concerning patients with normal or near-normal renal function, for whom dapagliflozin treatment is associated with reversible decreases in eGFR and long-term eGFR stabilization. Metformin-based total 6 (3. FIGURE 2 Adjusted mean change from baseline in eGFR (95% CI) during 24-week treatment period and 3-week follow-up period (safety analysis set). † Data analysed with missing data assumptions specific to the repeated measures model, with missing data considered to be missing at random. ‡ Data analysed separately using an extension of the analysis model to include Week 27, enabling the pattern in missing data to change with the inclusion of post-treatment follow-up. CI, confidence interval; eGFR, estimated glomerular filtration rate; SD, standard deviation events, elevated liver enzymes or liver-related AEs were reported. In addition, no AEs of bone fractures or amputations were reported during the study, consistent with previous studies. 29, 30 Limitations to this study include the timeframe, which was too short to assess long-term effects of dapagliflozin. Furthermore, the vast majority of patients were Caucasian (>87%), restricting generalizability of the results. Another potential limitation is that patients with recent CV events and a rapid decline in eGFR during the prerandomization visit were excluded, as were patients receiving certain glucose-lowering medications (ie, GLP-1 receptor agonists and rapid/ short-acting insulin).
As expected, glycaemic efficacy with dapagliflozin was lower than that reported in patients with normal renal function, consistent with previous studies on SGLT2 inhibitors 18, 24, 25 and in line with their mode of action, which is dependent on GFR and, subsequently, the filtered glucose load. 17 However, the clinical value of dapagliflozin was demonstrated within this population, including significant improvements in HbA1c and FPG, in addition to reductions in body weight, SBP, serum uric acid and UACR.
The long-term renal benefits of dapagliflozin in CKD are currently being explored in an ongoing renal outcomes study (NCT03036150;
DAPA-CKD). In addition, 2 CV outcome trials are currently in progress; these involve patients with T2D and either established CV disease or multiple CV risk factors (NCT01730534; DECLARE-TIMI 58) 31 or chronic heart failure (NCT03036124; DAPA-HF). The efficacy and safety of dapagliflozin in patients with T2D, albuminuria and moderate renal impairment is also being investigated in an ongoing study (NCT02547935).
In conclusion, significant improvements in HbA1c, body weight and SBP over 24 weeks in patients with T2D and stage 3A CKD were demonstrated with use of dapagliflozin, with no increase in AEs or serious AEs. The findings of this study support a positive benefit/risk profile of dapagliflozin in patients with T2D and CKD stage 3A.
